Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

Keyphrases

• BRCA2 100%
• BRCA1 Gene 100%
• BRCA2 Gene 100%
• Gene Alteration 100%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 100%
• Rucaparib 100%
• Prostate-specific Antigen Response 37%
• Response Rate 25%
• Breast Cancer Susceptibility Gene 1 (BRCA1) 25%
• Measurable Disease 25%
• Radiology Review 25%
• Cancer-related 12%
• Twice Daily 12%
• Anemia 12%
• Treatment-related Adverse Events 12%
• Safety Profile 12%
• Prostate Cancer 12%
• Cancer Clinical Trials 12%
• Tumor Subtype 12%
• Germ Cells 12%
• Antitumor Activity 12%
• Direct Therapy 12%
• Androgen Receptor 12%
• Solid Tumors 12%
• PARP Inhibitor (PARPi) 12%
• Two-line 12%
• Response Evaluation Criteria in Solid Tumors (RECIST) 12%
• Objective Response Rate 12%
• Taxane-based Chemotherapy 12%

Medicine and Dentistry

• Gene Mutation 100%
• BRCA1 100%
• BRCA2 100%
• Castration Resistant Prostate Cancer 100%
• Rucaparib 100%
• Prostate Specific Antigen 33%
• Antigen Response 33%
• Disease 22%
• Radiology 22%
• Somatics 11%
• Adverse Event 11%
• Clinical Trial 11%
• Anemia 11%
• Prostate Cancer 11%
• Antineoplastic Activity 11%
• Androgen Receptor 11%
• Solid Malignant Neoplasm 11%
• PARP Inhibitor 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Castration Resistant Prostate Cancer 100%
• Rucaparib 100%
• Prostate Specific Antigen 60%
• Disease 40%
• Adverse Event 20%
• Clinical Trial 20%
• Chemotherapy 20%
• Prostate Cancer 20%
• Antitumor Activity 20%
• Anemia 20%
• Taxane 20%
• Solid Malignant Neoplasm 20%
• Androgen Receptor 20%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 20%